Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador, Brazil.
Am J Kidney Dis. 2012 Jul;60(1):90-101. doi: 10.1053/j.ajkd.2011.12.025. Epub 2012 Mar 3.
Poor nutritional status and both hyper- and hypophosphatemia are associated with increased mortality in maintenance hemodialysis (HD) patients. We assessed associations of phosphate binder prescription with survival and indicators of nutritional status in maintenance HD patients.
Prospective cohort study (DOPPS [Dialysis Outcomes and Practice Patterns Study]), 1996-2008.
SETTING & PARTICIPANTS: 23,898 maintenance HD patients at 923 facilities in 12 countries.
Patient-level phosphate binder prescription and case-mix-adjusted facility percentage of phosphate binder prescription using an instrumental-variable analysis.
All-cause mortality.
Overall, 88% of patients were prescribed phosphate binders. Distributions of age, comorbid conditions, and other characteristics showed small differences between facilities with higher and lower percentages of phosphate binder prescription. Patient-level phosphate binder prescription was associated strongly at baseline with indicators of better nutrition, ie, higher values for serum creatinine, albumin, normalized protein catabolic rate, and body mass index and absence of cachectic appearance. Overall, patients prescribed phosphate binders had 25% lower mortality (HR, 0.75; 95% CI, 0.68-0.83) when adjusted for serum phosphorus level and other covariates; further adjustment for nutritional indicators attenuated this association (HR, 0.88; 95% CI, 0.80-0.97). However, this inverse association was observed for only patients with serum phosphorus levels ≥3.5 mg/dL. In the instrumental-variable analysis, case-mix-adjusted facility percentage of phosphate binder prescription (range, 23%-100%) was associated positively with better nutritional status and inversely with mortality (HR for 10% more phosphate binders, 0.93; 95% CI, 0.89-0.96). Further adjustment for nutritional indicators reduced this association to an HR of 0.95 (95% CI, 0.92-0.99).
Results were based on phosphate binder prescription; phosphate binder and nutritional data were cross-sectional; dietary restriction was not assessed; observational design limits causal inference due to possible residual confounding.
Longer survival and better nutritional status were observed for maintenance HD patients prescribed phosphate binders and in facilities with a greater percentage of phosphate binder prescription. Understanding the mechanisms for explaining this effect and ruling out possible residual confounding require additional research.
在维持性血液透析(HD)患者中,营养状况不良以及高磷血症和低磷血症均与死亡率增加相关。我们评估了磷结合剂处方与维持性 HD 患者的生存率和营养状况指标之间的关系。
前瞻性队列研究(DOPPS [透析结局和实践模式研究]),1996-2008 年。
12 个国家的 923 个设施中 23898 名维持性 HD 患者。
使用工具变量分析进行患者水平的磷结合剂处方和经过病例调整的设施中磷结合剂处方的百分比。
总体而言,88%的患者接受了磷结合剂处方。设施之间磷结合剂处方百分比的年龄、合并症和其他特征分布差异较小。基线时,患者水平的磷结合剂处方与更好的营养指标密切相关,即血清肌酐、白蛋白、校正蛋白分解率和体重指数较高,且无恶病质表现。总体而言,调整血清磷水平和其他协变量后,接受磷结合剂处方的患者死亡率降低了 25%(HR,0.75;95%CI,0.68-0.83);进一步调整营养指标会减弱这种关联(HR,0.88;95%CI,0.80-0.97)。然而,这种负相关仅见于血清磷水平≥3.5mg/dL 的患者。在工具变量分析中,经过病例调整的设施中磷结合剂处方的百分比(范围为 23%-100%)与更好的营养状况呈正相关,与死亡率呈负相关(每增加 10%的磷结合剂处方,HR 为 0.93;95%CI,0.89-0.96)。进一步调整营养指标将该关联降低至 HR 为 0.95(95%CI,0.92-0.99)。
结果基于磷结合剂处方;磷结合剂和营养数据为横断面;未评估饮食限制;观察性设计由于可能存在残余混杂因素,限制了因果推断。
接受磷结合剂处方的维持性 HD 患者和磷结合剂处方比例较高的设施中,患者生存率更高,营养状况更好。需要进一步的研究来了解解释这种效果的机制,并排除可能存在的残余混杂因素。